Adjunctive Antipsychotics in Major Depressive Disorder

阿立哌唑 奎硫平 重性抑郁障碍 医学 精神科 置信区间 荟萃分析 萧条(经济学) 辅助治疗 科克伦图书馆 评定量表 梅德林 精神分裂症(面向对象编程) 内科学 随机对照试验 奥氮平 非定型抗精神病薬 相对风险 儿科 双相情感障碍 不利影响 抑郁症状 需要治疗的数量 临床试验 重性抑郁发作 子群分析 富马酸奎硫平 精神病性抑郁症
作者
Roger S. McIntyre,Stephen M. Stahl,Sung Ryul Shim,Maurizio Pompili,Joseph F. Goldberg,Christoph Ulrich Correll,Angela T.H. Kwan,Christine E. Dri,Heidi Xu,Maj Vinberg,Taeho Greg Rhee
出处
期刊:JAMA Psychiatry [American Medical Association]
卷期号:83 (7): 741-741 被引量:10
标识
DOI:10.1001/jamapsychiatry.2026.0658
摘要

Importance: Most adults living with major depressive disorder (MDD) fail to achieve remission with conventional antidepressants. The US Food and Drug Administration (FDA) has approved 5 atypical antipsychotics in MDD on the basis of their substantial evidence of efficacy and safety. Objective: To compare the efficacy and acceptability of FDA-approved atypical antipsychotics for the adjunctive treatment of MDD in order to provide decision support to practitioners and persons with lived experience. Data Sources: A systematic search was conducted using PubMed/MEDLINE, PsycINFO, the Cochrane Library, and Embase from database inception through July 15, 2025. Study Selection: Six independent raters screened publications for eligibility. Inclusion criteria were atypical antipsychotics that are FDA approved in the adjunctive treatment of MDD. Data Extraction and Synthesis: Two independent raters obtained data and examined risk of bias in accordance with the Cochrane criteria. Effect sizes were synthesized using random-effects models. Data were analyzed from August to September 2025. Main Outcomes and Measures: The primary outcomes were efficacy (ie, ≥50% reduction from baseline in the total Montgomery-Åsberg Depression Rating Scale [MADRS] score) and acceptability (ie, all-cause discontinuation). Results: A total of 22 short-term studies comprising 10 962 participants (aripiprazole: n = 1297; brexpiprazole: n = 1973; cariprazine: n = 1894; lumateperone: n = 483; quetiapine extended release [XR]: n = 719; and placebo: n = 4596) were included for analysis. Lumateperone had the highest effect size for efficacy (risk ratio [RR], 1.72; 95% credible interval [CrI], 1.40-2.15), followed by aripiprazole (RR, 1.53; 95% CrI, 1.32-1.77), brexpiprazole (RR, 1.38; 95% CrI, 1.18-1.65), cariprazine (RR, 1.20; 95% CrI, 1.07-1.36), and quetiapine XR (RR, 1.15; 95% CrI, 0.96-1.35). A hierarchy of acceptability was observed, with aripiprazole exhibiting the highest acceptability (RR, 1.16; 95% CrI, 0.89-1.50), followed by cariprazine (RR, 1.44; 95% CrI, 1.15-1.82), brexpiprazole (RR, 1.47; 95% CrI, 1.18-1.85), quetiapine XR (RR, 1.56; 95% CrI, 1.14-2.12), and lumateperone (RR, 2.30; 95% CrI, 1.45-3.84). Secondary outcomes (eg, symptomatic remission) and exploratory outcomes (eg, clinically significant weight gain) accorded with the coprimary outcomes. Conclusions and Relevance: This systematic review and meta-analysis indicates that differences exist between adjunctive atypical antipsychotics in the treatment of MDD with respect to overall efficacy and acceptability, which should be simultaneously considered. The absence of adequate and well-controlled studies documenting maintenance efficacy of adjunctive atypical antipsychotics in MDD remains a knowledge gap.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
江城完成签到,获得积分10
刚刚
刚刚
衢夭完成签到,获得积分10
刚刚
鱼鱼完成签到,获得积分10
刚刚
蓝莓西西果冻完成签到,获得积分10
刚刚
tuimao发布了新的文献求助10
1秒前
田様的应助被hy采纳,获得10
1秒前
ChloeXW完成签到,获得积分10
1秒前
LI完成签到,获得积分10
2秒前
香蕉觅云的应助被RAIN采纳,获得10
3秒前
3秒前
犹豫的稀完成签到,获得积分10
3秒前
Daniel完成签到,获得积分10
4秒前
跳跃芷蕊完成签到,获得积分10
4秒前
情怀的应助被汉堡大王采纳,获得10
4秒前
5秒前
5秒前
小慈完成签到,获得积分10
5秒前
5秒前
adogi完成签到 ,获得积分20
5秒前
wyb完成签到,获得积分10
5秒前
科研民工完成签到,获得积分10
5秒前
整齐惋庭完成签到,获得积分10
5秒前
5秒前
6秒前
感性的楷瑞完成签到,获得积分10
6秒前
这朵蘑菇完成签到,获得积分10
6秒前
zz完成签到 ,获得积分10
6秒前
成就歌曲完成签到,获得积分10
6秒前
慕青的应助被tuimao采纳,获得10
7秒前
gcl发布了新的文献求助10
7秒前
7秒前
小王完成签到,获得积分10
7秒前
橘子海完成签到,获得积分10
7秒前
王珑完成签到 ,获得积分10
8秒前
YAOYAO完成签到,获得积分0
8秒前
曹广秀完成签到,获得积分10
8秒前
悲伤的茄子完成签到,获得积分10
8秒前
铁盐君完成签到,获得积分10
8秒前
海的呼唤完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173463
求助须知:如何正确求助?哪些是违规求助? 9565690
关于积分的说明 21781315
捐赠科研通 7767647
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476808